114 related articles for article (PubMed ID: 35196359)
1. Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome.
Starbuck JM; Llambrich S; Gonzàlez R; Albaigès J; Sarlé A; Wouters J; González A; Sevillano X; Sharpe J; De La Torre R; Dierssen M; Vande Velde G; Martínez-Abadías N
Sci Rep; 2021 Feb; 11(1):4715. PubMed ID: 33633179
[TBL] [Abstract][Full Text] [Related]
2. EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model.
Delabar JM; Gomes MAGB; Fructuoso M; Sarrazin N; George N; Fleary-Roberts N; Sun H; Bui LC; Rodrigues-Lima F; Janel N; Dairou J; Maria EJ; Dodd RH; Cariou K; Potier MC
Eur J Med Chem; 2024 Feb; 265():116098. PubMed ID: 38171148
[TBL] [Abstract][Full Text] [Related]
3. Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome.
Long R; Drawbaugh ML; Davis CM; Goodlett CR; Williams JR; Roper RJ
Complement Ther Med; 2019 Aug; 45():234-241. PubMed ID: 31331567
[TBL] [Abstract][Full Text] [Related]
4. Sex specific emergence of trisomic
LaCombe JM; Sloan K; Thomas JR; Blackwell MP; Crawford I; Wallace JM; Roper RJ
bioRxiv; 2024 May; ():. PubMed ID: 38826419
[TBL] [Abstract][Full Text] [Related]
5. Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus.
Granno S; Nixon-Abell J; Berwick DC; Tosh J; Heaton G; Almudimeegh S; Nagda Z; Rain JC; Zanda M; Plagnol V; Tybulewicz VLJ; Cleverley K; Wiseman FK; Fisher EMC; Harvey K
Sci Rep; 2019 May; 9(1):7322. PubMed ID: 31086297
[TBL] [Abstract][Full Text] [Related]
6. Dyrk1A is dynamically expressed on subsets of motor neurons and in the neuromuscular junction: possible role in Down syndrome.
Arque G; Casanovas A; Dierssen M
PLoS One; 2013; 8(1):e54285. PubMed ID: 23342120
[TBL] [Abstract][Full Text] [Related]
7. Compromised femoral and lumbovertebral bone in the Dp(16)1Yey Down syndrome mouse model.
Lamantia J; Sloan K; Wallace JM; Roper RJ
Bone; 2024 Apr; 181():117046. PubMed ID: 38336158
[TBL] [Abstract][Full Text] [Related]
8. Genetic dissection of triplicated chromosome 21 orthologs yields varying skeletal traits in Down syndrome model mice.
Sloan K; Thomas J; Blackwell M; Voisard D; Lana-Elola E; Watson-Scales S; Roper DL; Wallace JM; Fisher EMC; Tybulewicz VLJ; Roper RJ
Dis Model Mech; 2023 Apr; 16(4):. PubMed ID: 36939025
[TBL] [Abstract][Full Text] [Related]
9. Skeletal dynamics of Down syndrome: A developing perspective.
LaCombe JM; Roper RJ
Bone; 2020 Apr; 133():115215. PubMed ID: 31887437
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse model.
Llambrich S; Tielemans B; Saliën E; Atzori M; Wouters K; Van Bulck V; Platt M; Vanherp L; Gallego Fernandez N; Grau de la Fuente L; Poptani H; Verlinden L; Himmelreich U; Croitor A; Attanasio C; Callaerts-Vegh Z; Gsell W; Martínez-Abadías N; Vande Velde G
Elife; 2024 Mar; 12():. PubMed ID: 38497812
[TBL] [Abstract][Full Text] [Related]
11. Overexpression screen of chromosome 21 genes reveals modulators of Sonic hedgehog signaling relevant to Down syndrome.
Moyer AJ; Fernandez FX; Li Y; Klinedinst DK; Florea LD; Kazuki Y; Oshimura M; Reeves RH
Dis Model Mech; 2023 Apr; 16(4):. PubMed ID: 36995257
[TBL] [Abstract][Full Text] [Related]
12. Urinary and Daily Assumption of Polyphenols and Hip-Fracture Risk: Results from the InCHIANTI Study.
Pellegrino R; Paganelli R; Bandinelli S; Cherubini A; Andrés-Lacueva C; Di Iorio A; Sparvieri E; Zamora-Ros R; Ferrucci L
Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432441
[TBL] [Abstract][Full Text] [Related]
13. Green Tea Catechins Modulate Skeletal Development with Effects Dependent on Dose, Time, and Structure in a down Syndrome Mouse Model.
Llambrich S; González-Colom R; Wouters J; Roldán J; Salassa S; Wouters K; Van Bulck V; Sharpe J; Callaerts-Vegh Z; Vande Velde G; Martínez-Abadías N
Nutrients; 2022 Oct; 14(19):. PubMed ID: 36235819
[TBL] [Abstract][Full Text] [Related]
14. Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?
Martínez-Cué C; Bartesaghi R
Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889838
[TBL] [Abstract][Full Text] [Related]
15. Catechins as a Potential Dietary Supplementation in Prevention of Comorbidities Linked with Down Syndrome.
Noll C; Kandiah J; Moroy G; Gu Y; Dairou J; Janel N
Nutrients; 2022 May; 14(10):. PubMed ID: 35631180
[TBL] [Abstract][Full Text] [Related]
16. Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.
Jamal R; LaCombe J; Patel R; Blackwell M; Thomas JR; Sloan K; Wallace JM; Roper RJ
PLoS One; 2022; 17(2):e0264254. PubMed ID: 35196359
[TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
[TBL] [Abstract][Full Text] [Related]
18. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
